Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Heckl

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Cancer Cell|September 23, 2014
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDSRebekka K Schneider, Vera Ademà, Dirk Heckl, et al.
Leukemia|February 26, 2020
Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutationJulius Lukes, Petr Danek, Oriol Alejo-Valle, et al.
Journal of Hepatology|April 2, 2017
Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral loadSandra Westhaus, Maximilian Deest, Anna T X Nguyen, et al.
The Journal of Clinical Investigation|July 21, 2015
Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosisRafael Kramann, Susanne V Fleig, Rebekka K Schneider, et al.
Theranostics|September 1, 2020
LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1Stella Logotheti, Stephan Marquardt, Shailendra K Gupta, et al.
Iscience|September 28, 2023
Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus <i>MYNRL15</i>Michelle Ng, Lonneke Verboon, Hasan Issa, et al.
Leukemia|October 3, 2019
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)Tatjana Meyer, Nikolaus Jahn, Stefanie Lindner, et al.
Science (New York, N.Y.)|December 3, 2013
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsJan Krönke, Namrata D Udeshi, Anupama Narla, et al.
Blood Advances|May 5, 2021
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaStephan R Bohl, Laura K Schmalbrock, Imke Bauhuf, et al.
Leukemia|June 25, 2020
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaArnold Kloos, Konstantinos Mintzas, Lina Winckler, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Cancer Cell|September 23, 2014
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDSRebekka K Schneider, Vera Ademà, Dirk Heckl, et al.
Leukemia|February 26, 2020
Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutationJulius Lukes, Petr Danek, Oriol Alejo-Valle, et al.
Journal of Hepatology|April 2, 2017
Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral loadSandra Westhaus, Maximilian Deest, Anna T X Nguyen, et al.
The Journal of Clinical Investigation|July 21, 2015
Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosisRafael Kramann, Susanne V Fleig, Rebekka K Schneider, et al.
Theranostics|September 1, 2020
LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1Stella Logotheti, Stephan Marquardt, Shailendra K Gupta, et al.
Iscience|September 28, 2023
Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus <i>MYNRL15</i>Michelle Ng, Lonneke Verboon, Hasan Issa, et al.
Leukemia|October 3, 2019
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)Tatjana Meyer, Nikolaus Jahn, Stefanie Lindner, et al.
Science (New York, N.Y.)|December 3, 2013
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsJan Krönke, Namrata D Udeshi, Anupama Narla, et al.
Blood Advances|May 5, 2021
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaStephan R Bohl, Laura K Schmalbrock, Imke Bauhuf, et al.
Leukemia|June 25, 2020
Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemiaArnold Kloos, Konstantinos Mintzas, Lina Winckler, et al.
Pageof 6